BU
AZN icon

BBVA USA’s AstraZeneca AZN Stock Holding History

BBVA USA’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$33K Buy
+275
New +$32K ﹤0.01% 721

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BBVA USA's AZN Position: Q3 2021 in Review

BBVA USA opened a new position in AstraZeneca (AZN) in Q3 2021: 275 shares worth $33K. The stake represents ﹤0.01% of the portfolio and ranks #721 among its holdings.

906 funds tracked by Wall St. Rank hold AZN as of Q3 2021.

  • BBVA USA held 275 shares of AstraZeneca worth $33K as of Q3 2021.
  • AstraZeneca was a new BBVA USA position in Q3 2021.
  • AstraZeneca made up ﹤0.01% of BBVA USA's portfolio in Q3 2021, its #721 holding.
  • 906 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.